Evidence map›Paper›PMID 41861751›Full record

ArticleESMO open2026

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.

H S Rugo, S M Tolaney, J Cortés, F Marmé, E de Azambuja, B Xu, J Sohn, Y Naito, T Valdez, D Gary and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

H S RugoCity of Hope, Duarte, CA, USA. Electronic address: hrugo@coh.org.
S M TolaneyDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
J CortésOncology Department, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain; IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain; Oncology Department, Hospital Universitario Torrejón, Ribera Group, Madrid, Spain; Department of Medicine, Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Madrid, Spain; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain.
F MarméMedical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
E de AzambujaInstitut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), l'Université Libre de Bruxelles (ULB), Brussels, Belgium.
B XuCancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
J SohnYonsei Cancer Center, Seoul, Republic of Korea.
Y NaitoNational Cancer Center Hospital East, Kashiwa, Japan.
T ValdezGilead Sciences, Inc., Foster City, CA, USA.
D GaryGilead Sciences, Inc., Foster City, CA, USA.
J ZhuGilead Sciences, Inc., Shanghai, China.
C LaiGilead Sciences, Inc., Foster City, CA, USA.
A BardiaDavid Geffen School of Medicine, University of California, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSacituzumab govitecan (SG) is an antibody-drug conjugate that has significantly improved survival outcomes versus standard of care across multiple studies in patients with previously treated metastatic breast cancer (mBC). Cancer treatment is associated with differing rates of treatment-emergent adverse events (TEAEs) based on patient race/location. We evaluated consistency and manageability of SG safety in mBC across multiple clinical studies and regions in this pooled analysis. MATERIALS AND

methodsSafety data for patients who received SG treatment (10 mg/kg, days 1 and 8 every 21-day cycle) were pooled from clinical studies in North America/Europe (NA/EU; ASCENT, TROPiCS-02, IMMU-132-01) and Asia (EVER-132-001, EVER-132-002, ASCENT-J02).

resultsThe analysis included 969 patients (688 NA/EU, 281 Asia). In NA/EU, 74% of patients experienced grade ≥3 TEAEs. TEAEs leading to treatment discontinuation (5%) or death (1%) were uncommon. The most common TEAEs were neutropenia, nausea, and diarrhea. The safety profile was similar for patients in Asia, with 78% experiencing grade ≥3 TEAEs and low rates of TEAEs leading to treatment discontinuation (4%) or death (3%). Neutropenia, anemia, leukopenia, increased aspartate aminotransferase, increased alanine aminotransferase, and hypoalbuminemia were more frequently reported in Asia versus NA/EU; diarrhea and fatigue were more common in NA/EU.

conclusionsThe safety profile of SG was manageable and consistent with previous studies, with low rates of TEAEs leading to treatment discontinuation or death; some differences in TEAE rates were observed between NA/EU and Asia. This analysis provides further support for SG as a treatment for mBC across multiple patient subgroups.

Indexed as

Antibodies, Monoclonal, HumanizedBreast NeoplasmsCamptothecinAdultAgedAsiaEuropeFemaleHumansImmunoconjugatesMiddle AgedNeoplasm MetastasisNorth AmericaAntibodies, Monoclonal, HumanizedCamptothecinImmunoconjugatessacituzumab govitecanHR-positive/HER2-negative metastatic breast cancermetastatic triple-negative breast cancerpooled analysissacituzumab govitecansafety

Identifiers

PMID41861751
PMCPMC13010465

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.